Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lestaurtinib (CEP-701)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Kyowa Kirin, Teva

Drug class:

JAK2 inhibitor, FLT3 inhibitor, STAT5 inhibitor

Related drugs:

‹

entrectinib (178)

ruxolitinib (73)

momelotinib (2)

tofacitinib (1)

FAK-JAK 2 dual Inhib (0)

flonoltinib (0)

BS-HH-002.SA (0)

quizartinib (40)

ripretinib (11)

pexidartinib (6)

›

KMT2A rearrangement	Acute Lymphocytic Leukemia	KMT2A rearrangement	Acute Lymphocytic Leukemia	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	trametinib + CEP-701 Sensitive: D – Preclinical trametinib + CEP-701 Sensitive : D	trametinib + CEP-701 Sensitive: D – Preclinical trametinib + CEP-701 Sensitive : D